MyFinsight
Home
Blog
About
Contact
Download
Download image
Product
$283,003K
(43.92%↑ Y/Y)
Royalty Contract And
Other Revenue
$8,842K
(37.43%↑ Y/Y)
Product revenue, net
$291,845K
(43.72%↑ Y/Y)
Income (loss) from
operations
$24,896K
(173.99%↑ Y/Y)
Total costs and
expenses
$266,949K
(12.77%↑ Y/Y)
Net income (loss)
before income taxes
$554K
(100.97%↑ Y/Y)
Total other expense
-$24,342K
(-3.77%↓ Y/Y)
Interest and other income
$4,742K
(-10.88%↓ Y/Y)
Selling, general and
administrative
$182,372K
(11.56%↑ Y/Y)
Cost of goods sold
$42,569K
(15.58%↑ Y/Y)
Research and development
$31,165K
(21.93%↑ Y/Y)
Amortization of intangible
assets
$10,843K
(0.00%↑ Y/Y)
Net income (loss)
$554K
(101.01%↑ Y/Y)
Interest expense
$29,084K
(-4.60%↓ Y/Y)
Comprehensive income (loss)
$554K
(101.01%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)